Table 1.
Baseline Characteristics
| Characteristic | Time to Undetectable Analysis (n = 804) | Time to Rebound Analysis (n = 784) |
|---|---|---|
| Age, n (%) | ||
| <40 years | 341 (42.4) | 310 (39.5) |
| 40-49 years | 277 (34.5) | 281 (35.8) |
| ≥50 years | 186 (23.1) | 193 (24.6) |
| Male gender, n (%) | 707 (87.9) | 682 (87.0) |
| Race, n (%) | ||
| White | 471 (58.6) | 484 (61.7) |
| Black | 156 (19.4) | 127 (16.2) |
| Hispanic | 117 (14.6) | 102 (13.0) |
| Other/unknown | 60 (7.5) | 71 (9.1) |
| HIV Risk Factors, n (%) | ||
| MSM | 422 (52.5) | 427 (54.5) |
| Heterosexual | 141 (17.5) | 133 (17.0) |
| IDU | 61 (7.6) | 49 (6.3) |
| Other/unknown | 180 (22.4) | 175 (22.3) |
| Hepatitis B, n (%) | 58 (7.2) | 55 (7.0) |
| Hepatitis C, n (%) | 82 (10.2) | 79 (10.1) |
| Mean baseline CD4+ cell count, n (%)a | ||
| < 200 cells/mm3 | 323 (41.4) | 224 (29.6) |
| 200-499 cells/mm3 | 342 (43.8) | 333 (44.1) |
| ≥ 500 cells/mm3 | 116 (14.9) | 199 (26.3) |
| Mean baseline HIV RNA, n (%)a | ||
| <75 copies/mL | - | 343 (43.8) |
| 75-999 copies/mL | 158 (19.7) | 105 (13.4) |
| 1,000-9,999 copies/mL | 169 (21.0) | 70 (8.9) |
| ≥ 10,000 copies/mL | 477 (59.3) | 266 (33.9) |
| Twice daily dosing of Nelfinavir, n (%) | 566 (70.4) | 570 (72.7) |
| Proton Pump Inhibitor use, n (%) | ||
| PPI use | 89 (11.1) | 103 (13.1) |
| PPI initiated before NFV | 41 (46.1)b | 36 (35.0)b |
| PPI initiated after NFV | 48 (53.9)b | 67 (65.0)b |
| Ever use of CYP 3A4 inducers, n (%) | 301 (37.4) | 224 (28.6) |
| Ever use of CYP 2C19 inhibitors, n (%) | 76 (9.5) | 85 (10.8) |
| Ever pregnant, n (%) | 15 (15.5) | 14 (13.7) |
a
Baseline laboratory values are from prior to the initiation of nelfinavir
b
Calculated based on percentage of total PPI use